Janux Therapeutics, Inc. quarterly report, Q1 FY2024

Janux Therapeutics, Inc. — Q1 2024 Form 10-Q

Reporting period: Three months ended March 31, 2024; filed May 7, 2024. Janux is a clinical-stage biopharmaceutical company developing tumor-activated cancer immunotherapies. It has no product sales and is not profitable.

Financial results and liquidity

Metric	Q1 2024	Q1 2023 / prior date
Collaboration revenue	$1.252 million	$2.048 million
Research and development expense	$14.070 million	$15.865 million
General and administrative expense	$7.343 million	$6.464 million
Total operating expenses	$21.413 million	$22.329 million
Loss from operations	$20.161 million	$20.281 million
Interest income	$5.401 million	$2.822 million
Net loss	$14.760 million; $0.30 per share	$17.459 million; $0.42 per share
Cash used in operating activities	$14.837 million	$13.911 million

At March 31, cash and cash equivalents were $212.8 million and short-term investments were $439.0 million; restricted cash of $0.8 million was not available for current use. Total cash, cash equivalents, restricted cash and short-term investments were $652.6 million.
Total assets were $689.0 million, total liabilities $33.2 million, and stockholders’ equity $655.8 million. The filing reports no borrowings; operating lease liabilities totaled $24.2 million.
Current liabilities were $10.6 million versus current assets of $658.7 million. The company reported an accumulated deficit of $183.5 million.
Operating margin and product-level margins are not meaningful given the company’s development-stage operations and lack of product revenue.

Material changes versus the prior comparable period

Revenue declined $0.8 million, or about 39%, primarily because fewer full-time-equivalent research hours were performed under the Merck collaboration.
R&D expense fell $1.8 million, mainly due to lower preclinical and unallocated direct costs, partly offset by higher JANX007 and indirect costs. G&A expense rose $0.9 million, reflecting higher stock compensation, personnel and facilities costs, and other expenses.
Net loss narrowed by $2.7 million. Higher interest income contributed $2.6 million of the improvement; loss from operations was broadly unchanged.
March cash flows included $322.2 million of financing inflows, principally proceeds from the March underwritten stock and pre-funded warrant offering. Net proceeds were approximately $320.1 million after $20.9 million of issuance costs. The offering included 5.40 million common shares and warrants for 1.94 million shares, increasing potential dilution.
Cash, cash equivalents and restricted cash increased $193.6 million during the quarter. Investing cash outflow was $113.7 million, largely reflecting net purchases of short-term investments.

Outlook, commentary and risks

Management expects existing cash, cash equivalents and short-term investments to fund anticipated operating expenses and capital expenditures for at least 12 months following the filing. It also says additional capital will be needed to complete development and commercialization; there is no assurance financing will be available on acceptable terms.
Janux expects substantial operating losses and higher expenses for the foreseeable future. Its lead programs, JANX007 and JANX008, are in Phase 1 trials; other programs are preclinical or in discovery. The filing reports company-announced interim data for both programs, but cautions that interim and preliminary clinical results can change and may not predict later results.
Management described February 2024 interim JANX007 data as showing PSA declines, a favorable safety profile, low-grade cytokine release syndrome (CRS), and pharmacokinetics consistent with the platform’s mechanism. It described early JANX008 data as showing anti-tumor activity in multiple tumor types, low-grade CRS, and predominantly low-grade treatment-related adverse events. These are company-reported early findings, not evidence of approval or established efficacy.
The Merck agreement provides research funding and potential development, regulatory and commercial milestones and royalties. Merck may terminate at its discretion; future milestone and royalty receipts depend on development and commercialization outcomes. All reported revenue in both comparison periods came from one customer.
Key risks include clinical failure or delays, patient enrollment, serious adverse events including CRS and healthy-tissue toxicity, reliance on third-party manufacturers and clinical research organizations, potential financing needs and dilution, intellectual-property challenges, and macroeconomic, interest-rate and banking-market uncertainty. The company said it had experienced no material operational disruption from the cited macroeconomic risks to date.
Operating lease liabilities were $24.2 million, with $34.1 million of undiscounted minimum lease payments. The company reported no material legal proceedings. Its ATM sales agreement prospectus was suspended and terminated in February 2024; no ATM sales occurred in the quarter, and sales require a new prospectus or registration filing.

Important facts for investors to verify

Review subsequent JANX007 and JANX008 clinical updates, including patient numbers, follow-up, durability, adverse events, and whether early findings are confirmed in larger datasets.
Assess the timing and expected cost of clinical trials, manufacturing, and other development plans against the reported $652.6 million of cash, cash equivalents, restricted cash and investments; runway is management’s estimate and may change.
Check the share and warrant count following the March offering, warrant exercises, and equity compensation. The filing reported 51.84 million common shares outstanding at March 31 and 51.85 million as of May 3, 2024.
Track Merck research obligations, target progress, collaboration revenue, and any milestones or royalties actually achieved; potential payments are contingent, not guaranteed.
Monitor interest-rate effects on investment values and liquidity, as well as the company’s ability to secure future funding without material dilution or unfavorable terms.